X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Recommendation of “Moderate Buy” from Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $9.3750.

XFOR has been the subject of several recent analyst reports. Leerink Partners initiated coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 4th. Finally, Guggenheim began coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 price target for the company.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of institutional investors have recently made changes to their positions in XFOR. Empery Asset Management LP acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at about $35,804,000. Perceptive Advisors LLC acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at about $25,258,000. Bain Capital Life Sciences Investors LLC increased its position in shares of X4 Pharmaceuticals by 227.0% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock valued at $31,870,000 after acquiring an additional 5,530,866 shares during the last quarter. Kalehua Capital Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at about $14,891,000. Finally, Braidwell LP acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at about $13,476,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $3.88 on Friday. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $4.83. The stock has a market cap of $365.96 million, a P/E ratio of -0.85 and a beta of 0.34. The company has a 50-day moving average price of $4.09 and a 200 day moving average price of $3.89. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The firm had revenue of $2.71 million during the quarter, compared to analysts’ expectations of $3.20 million. Sell-side analysts anticipate that X4 Pharmaceuticals will post -0.77 earnings per share for the current year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.